Safety and Efficacy of γδ T Cell Against Gastric Cancer
NCT ID: NCT02585908
Last Updated: 2019-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
120 participants
INTERVENTIONAL
2019-12-31
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer
NCT01637805
Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer
NCT02425735
Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer
NCT02496273
Dendritic Cell-based Immunotherapy in Treatment Gastric Cancer
NCT03410732
Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)
NCT02425748
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental Group A(control group)
regular treatment and follow up
No interventions assigned to this group
Experimental Group B
CIK will be used against tumor cells.
CIK
CIK cells will be used against tumor cells.
Experimental Group C
γδ T will be used against tumor cells.
γδ T
γδ T cells will be used against tumor cells.
Experimental Group D
CIK and γδ T will be used against tumor cells.
CIK and γδ T
CIK and γδ T cells will be used against tumor cells.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CIK
CIK cells will be used against tumor cells.
γδ T
γδ T cells will be used against tumor cells.
CIK and γδ T
CIK and γδ T cells will be used against tumor cells.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Karnofsky performance status \>50
3. Diagnosis with gastric cancer based on histology or the current accepted radiological measures.
4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ
5. Patients who have a life expectancy of at least 12 weeks
6. Ability to understand the study protocol and a willingness to sign a written informed consent document
Exclusion Criteria
2. Known human immunodeficiency virus (HIV) infection.
3. Active and/or severe infection (e.g. tuberculosis, sepsis and opportunistic infections, active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection).
4. Other serious underlying medical conditions, which, in the Investigator's judgment, could impair the ability of the patient.
5. Pregnancy
30 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Doing Biomedical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
li gangyi, master
Role: STUDY_CHAIR
Beijing Doing Biomedical Co., Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
Huai'An First People'S Hospital
Huaian, Jiangsu, China
Hangzhou Cancer Hospital
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Doing-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.